Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis

Back to Search
Print
Bookmark Trial

NCT00884468

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Reus, Tarragona, 43201, Spain
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients both genders over 18 years old

- Patients with PsA diagnosis

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with PsA that suffer from other rheumatologic diseases or non-concomitant
rheumatologic diseases that the investigator considers not to be appropriate for the
study.


- Patients with any medical or physical condition (cognitive damage or difficulties for
understanding) that create difficulties for reading and completing the questionnaires
described in the protocol.


- Patients that in the study period are taking part in another clinical trial.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Psoriatic ArthritisStudy To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
NCT04428502
  1. Baghdad,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Psoriatic ArthritisStudy Evaluating the Safety of Enbrel (Etanercept)
NCT00683384
  1. Metro Manila,
ALL GENDERS
0+
years
MULTIPLE SITES
Psoriatic ArthritisStudy Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
NCT00245960
  1. Buenos Aires,
  2. Buenos Aires,
  3. Buenos Aires,
  4. Fitzroy Victoria,
  5. Liverpool,
  6. Graz,
  7. Wien,
  8. Ghent,
  9. Liege,
  10. Havlickova,
  11. Praha,
  12. Zlin,
  13. Hellerup,
  14. Horsholm,
  15. Kopenhavn NV,
  16. Odense C,
  17. Roskilde,
  18. Abo,
  19. Helsinki,
  20. Oulu,
  21. Tampere,
  22. Bordeaux,
  23. Brest,
  24. Caen Cedex,
  25. Creteil,
  26. Le Mans Cedex,
  27. Limoges,
  28. Nice Cedex,
  29. Paris Cedex,
  30. Paris,
  31. Pierre Bénite,
  32. Poitiers,
  33. Rouen Cedex,
  34. Tours,
  35. Bad Bentheim,
  36. Berlin,
  37. Berlin,
  38. Berlin,
  39. Berlin,
  40. Berlin,
  41. Bonn,
  42. Erlangen,
  43. Frankfurt-am-Main,
  44. Hamburg,
  45. Hamburg,
  46. Jena,
  47. Mahlow,
  48. München,
  49. Osnabruck,
  50. Wurzburg,
  51. Athens,
  52. Thessaloniki,
  53. Budapest,
  54. Debrecen,
  55. Kodaly,
  56. Koranyi,
  57. Miskolc,
  58. Szolnok,
  59. Brescia,
  60. Cagliari,
  61. Catania,
  62. Catania,
  63. Milano,
  64. Milano,
  65. Monserrato,
  66. Orbassano TO,
  67. Parma,
  68. Perugia,
  69. Roma,
  70. Roma,
  71. Siena,
  72. Torino,
  73. Trieste,
  74. Verona,
  75. Verona,
  76. Seoul,
  77. Seoul,
  78. Guadalajara,
  79. Mexico D.F.,
  80. CX Voorburg,
  81. DD Vlissingen,
  82. GL Nijmegen,
  83. HX Maastricht,
  84. Bydgoszcz,
  85. Lublin,
  86. Warszawa,
  87. Warszawa,
  88. Coimbra,
  89. Porto,
  90. Ryiad,
  91. Belgrade,
  92. Niska,
  93. Novi Sad,
  94. Zemun,
  95. Barcelona,
  96. Barcelona,
  97. Las Palmas de GC,
  98. Leganes,
  99. Madrid,
  100. Puerto Real,
  101. San Sebastian,
  102. Jonkoping,
  103. Umea,
  104. Uppsala,
  105. Lausanne,
  106. Zürich,
  107. Kaohsiung County,
  108. Taipei,
  109. Ankara,
  110. Aberdeen,
  111. Cardiff,
  112. Harrogate,
  113. Leeds,
  114. London,
  115. London,
  116. Nuneaton,
  117. Salford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Psoriatic ArthritisStudy Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis
NCT00580632
ALL GENDERS
19 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis
Official Title Anxiety and Depression in Patients With Psoriatic Arthritis: Prevalence and Characteristics
Brief Summary This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients with PsA from outpatient's surgery or primary health care centres
Condition Psoriatic Arthritis
Intervention Not Provided
Study Groups/Cohorts 1
Patients with PsA that fulfill the eligibility criteria of the study
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: April 17, 2009)		384
Original Actual Enrollment Same as current
Actual Study Completion Date December 2008
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion criteria:

  • Patients both genders over 18 years old
  • Patients with PsA diagnosis

Exclusion criteria:

  • Patients with PsA that suffer from other rheumatologic diseases or non-concomitant rheumatologic diseases that the investigator considers not to be appropriate for the study.
  • Patients with any medical or physical condition (cognitive damage or difficulties for understanding) that create difficulties for reading and completing the questionnaires described in the protocol.
  • Patients that in the study period are taking part in another clinical trial.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT00884468
Other Study ID Numbers 0881A5-4468
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date May 2009